Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).
暂无分享,去创建一个
Won-Tak Choi | Won-Tak Choi | J. An | Ziwei Huang | Jing An | Ziwei Huang | Yan Xu | Yan Xu | Srinivas Duggineni | S. Duggineni
[1] M. Lederman,et al. Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult Evolution from CCR5 to CXCR4 Coreceptor Use , 2011, PloS one.
[2] W. O'brien,et al. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions , 1996, Journal of virology.
[3] H. Makino,et al. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[4] Mike Youle,et al. Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir , 2006, Journal of Virology.
[5] D. Dimitrov,et al. Evidence for Cell-Surface Association Between Fusin and the CD4-gp120 Complex in Human Cell Lines , 1996, Science.
[6] H. Tamamura,et al. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. , 2007, Current medicinal chemistry.
[7] O. Meucci,et al. Human immunodeficiency virus gp120-induced apoptosis of human neuroblastoma cells in the absence of CXCR4 internalization , 2006, Journal of NeuroVirology.
[8] Jian-ye Yang,et al. Adenovirus-mediated stromal cell-derived- factor-1alpha gene transfer induces cardiac preservation after infarction via angiogenesis of CD133+ stem cells and anti-apoptosis. , 2008, Interactive cardiovascular and thoracic surgery.
[9] J. An,et al. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists , 2011, Experimental biology and medicine.
[10] J. Sodroski,et al. Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines* , 2002, The Journal of Biological Chemistry.
[11] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[12] Cimona V Hinton,et al. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain , 2010, Clinical & Experimental Metastasis.
[13] J. Barretina,et al. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. , 2000, AIDS research and human retroviruses.
[14] E. Fernandez,et al. Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 “fusin” coreceptor , 1998 .
[15] E. Kremmer,et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. , 1998, Journal of immunology.
[16] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[17] J. Dipersio,et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells , 2010, Current opinion in hematology.
[18] S. Climie,et al. Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. , 1995, Drugs under experimental and clinical research.
[19] N Tsukada,et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.
[20] T. Schulz,et al. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? , 1991, AIDS research and human retroviruses.
[21] F. Breedveld,et al. Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue. , 1998, Clinical immunology and immunopathology.
[22] E. De Clercq,et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] Hyunsuk Shim,et al. Discovery of small molecule CXCR4 antagonists. , 2007, Journal of medicinal chemistry.
[24] S. Fricker,et al. CXCR4 in clinical hematology. , 2010, Current topics in microbiology and immunology.
[25] B. Kobilka,et al. Adrenergic receptors as models for G protein-coupled receptors. , 1992, Annual review of neuroscience.
[26] M. Mizutani,et al. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. , 2004, Journal of medicinal chemistry.
[27] F. Breedveld,et al. Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. , 1996, British journal of rheumatology.
[28] Bernhard Moser,et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.
[29] R. Doms,et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] R. Doms,et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. , 2001, AIDS research and human retroviruses.
[31] R. Brezinschek,et al. Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. , 1996, Arthritis and rheumatism.
[32] R. Gorlin,et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.
[33] E. De Clercq,et al. Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication. , 2011, Bioorganic & medicinal chemistry letters.
[34] H. Dohlman,et al. Identification of Allosteric Peptide Agonists of CXCR4* , 2003, The Journal of Biological Chemistry.
[35] Lei Zhang,et al. Adenovirus-mediated stromal cell-derived factor-1 alpha gene transfer improves cardiac structure and function after experimental myocardial infarction through angiogenic and antifibrotic actions , 2009, Molecular Biology Reports.
[36] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[37] Ken Jacobson,et al. JNK phosphorylates paxillin and regulates cell migration , 2003, Nature.
[38] C. Strader,et al. Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.
[39] P. Chakravarty,et al. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells , 2009, Molecular Cancer Therapeutics.
[40] R. Leurs,et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells , 2010, Proceedings of the National Academy of Sciences.
[41] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[42] Ying Li,et al. Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus and d-Amino Acid-Containing Chemokine , 2007, Journal of Virology.
[43] Q. Sattentau,et al. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.
[44] C. Begley,et al. Broad inter‐individual variations in circulating progenitor cell numbers induced by granulocyte colony‐stimulating factor therapy , 1995, Stem cells.
[45] N. Yamamoto,et al. Ligand‐independent higher‐order multimerization of CXCR4, a G‐protein‐coupled chemokine receptor involved in targeted metastasis , 2009, Cancer science.
[46] Won-Tak Choi,et al. Unique Ligand Binding Sites on CXCR4 Probed by a Chemical Biology Approach: Implications for the Design of Selective Human Immunodeficiency Virus Type 1 Inhibitors , 2005, Journal of Virology.
[47] A. Proudfoot. Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.
[48] Dominique Schols,et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. , 2010, Journal of medicinal chemistry.
[49] J. Park,et al. Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects , 2007, Antimicrobial Agents and Chemotherapy.
[50] J. Sodroski,et al. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand. , 2005, Journal of medicinal chemistry.
[51] N. Yoshida,et al. A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.
[52] I. Sabroe,et al. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo. , 1998, Journal of immunology.
[53] T. Schwartz,et al. Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor* , 2001, The Journal of Biological Chemistry.
[54] G. Sharma,et al. p38 and ERK1/2 Coordinate Cellular Migration and Proliferation in Epithelial Wound Healing , 2003, Journal of Biological Chemistry.
[55] P. Lipsky,et al. Stromal Cell-Derived Factor-1-CXC Chemokine Receptor 4 Interactions Play a Central Role in CD4+ T Cell Accumulation in Rheumatoid Arthritis Synovium1 , 2000, The Journal of Immunology.
[56] P. Kubes,et al. Role of p38 Mitogen-Activated Protein Kinase in Chemokine-Induced Emigration and Chemotaxis In Vivo1 , 2001, The Journal of Immunology.
[57] V. Robert-Hebmann,et al. Binding of Human Immunodeficiency Virus Type 1 gp120 to CXCR4 Induces Mitochondrial Transmembrane Depolarization and Cytochromec-Mediated Apoptosis Independently of Fas Signaling , 2001, Journal of Virology.
[58] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[59] G. Landreth,et al. Involvement of p90rsk in Neurite Outgrowth Mediated by the Cell Adhesion Molecule L1* , 1996, The Journal of Biological Chemistry.
[60] Yuetsu Tanaka,et al. The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100 , 2009, Antimicrobial Agents and Chemotherapy.
[61] K. Auguste,et al. Global gene and cell replacement strategies via stem cells , 2002, Gene Therapy.
[62] J. D. Macklis,et al. Multipotent neural precursors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[63] N. Aiyar,et al. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. , 2001, Immunology letters.
[64] B. Dewald,et al. N-terminal Peptides of Stromal Cell-derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities* , 1998, Journal of Biological Chemistry.
[65] R. Doms,et al. A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.
[66] M. Goldsmith,et al. Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.
[67] Kenji Hayashida,et al. Stromal Cell-Derived Factor-1-CXC Chemokine Receptor 4 Interactions Play a Central Role in CD4+ T Cell Accumulation in Rheumatoid Arthritis Synovium1 , 2000, The Journal of Immunology.
[68] U. Schumacher,et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. , 2011, Journal of medicinal chemistry.
[69] Marc Parmentier,et al. Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.
[70] Jean Salamero,et al. HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.
[71] Julie L Prior,et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. , 2009, Blood.
[72] E. Hersh,et al. Cells Capable of Colony Formation in the Peripheral Blood of Man , 1971, Science.
[73] E. Freed,et al. HIV-1 Replication , 2001, Somatic cell and molecular genetics.
[74] T. Schwartz,et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. , 1997, Science.
[75] A. Trautmann,et al. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides , 1998, Current Biology.
[76] J. Benovic,et al. Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.
[77] E. De Clercq,et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. , 2000, Molecular pharmacology.
[78] Dominique Schols,et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. , 2005, Biochemical pharmacology.
[79] P. Murphy. The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.
[80] G. Ciaramella,et al. Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry , 2006, Journal of Virology.
[81] W. Messer. Bivalent ligands for G protein-coupled receptors. , 2004, Current pharmaceutical design.
[82] J. Hall,et al. Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide. , 1999, Biochemical and biophysical research communications.
[83] A. Billiau,et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis , 2005, Arthritis research & therapy.
[84] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[85] J. Gershoni,et al. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[86] Yang D. Teng,et al. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue , 2002, Nature Biotechnology.
[87] B. Clotet,et al. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro , 2008, AIDS.
[88] Massimo Cristofanilli,et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. , 2009, The Journal of surgical research.
[89] J. Sodroski,et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.
[90] P. Lipsky,et al. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. , 1997, The Journal of clinical investigation.
[91] S. Galli,et al. Mast Cells Can Amplify Airway Reactivity and Features of Chronic Inflammation in an Asthma Model in Mice , 2000, The Journal of experimental medicine.
[92] Kedar S Vaidya,et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. , 2009, Oncology reports.
[93] J. Goudsmit,et al. ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITY , 1989, The Lancet.
[94] J. Gutkind,et al. Viral hijacking of G-protein-coupled-receptor signalling networks , 2004, Nature Reviews Molecular Cell Biology.
[95] Eric J Topol,et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy , 2003, The Lancet.
[96] M. Matsuoka,et al. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. , 2008, Bioorganic & medicinal chemistry letters.
[97] E. Major,et al. M- and T-tropic HIVs Promote Apoptosis in Rat Neurons , 2009, Journal of Neuroimmune Pharmacology.
[98] W. Gerthoffer,et al. p21-activated kinase 1 participates in tracheal smooth muscle cell migration by signaling to p38 Mapk. , 2001, American journal of physiology. Cell physiology.
[99] Beverly A. Teicher,et al. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.
[100] M. Parmentier,et al. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of “Selective” Antagonists* , 2009, The Journal of Biological Chemistry.
[101] M. Salmon,et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. , 2003, Arthritis and rheumatism.
[102] Dominique Schols,et al. AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice1 , 2001, The Journal of Immunology.
[103] J. Ramachandran,et al. Structure and Function of G Protein Coupled Receptors , 1990, Pharmaceutical Research.
[104] D. Follmann,et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. , 2010, The Journal of infectious diseases.
[105] O. Kollet,et al. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2mnull mice , 2002, Leukemia.
[106] L. Pelus. Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand , 2008, Current opinion in hematology.
[107] P. Anderson,et al. Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. , 1988, The American journal of medicine.
[108] M. Ruzek,et al. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. , 2009, Biochemical pharmacology.
[109] D. S. Garrett,et al. High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. , 1994, Science.
[110] Won-Tak Choi,et al. Distinct Functional Sites for Human Immunodeficiency Virus Type 1 and Stromal Cell-Derived Factor 1α on CXCR4 Transmembrane Helical Domains , 2005, Journal of Virology.
[111] Gregory J Babcock,et al. Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.
[112] Yan Huang,et al. Stromal Cell–Derived Factor-1α Plays a Critical Role in Stem Cell Recruitment to the Heart After Myocardial Infarction but Is Not Sufficient to Induce Homing in the Absence of Injury , 2004, Circulation.
[113] J. Juarez,et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment , 2007, Leukemia.
[114] S. Srinivasula,et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[115] R. Cooke,et al. The three-dimensional solution structure of RANTES. , 1995, Biochemistry.
[116] M. Kaul,et al. Neuronal Apoptotic Signaling Pathways Probed and Intervened by Synthetically and Modularly Modified (SMM) Chemokines* , 2007, Journal of Biological Chemistry.
[117] S. Chensue,et al. AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. , 2006, The American journal of pathology.
[118] C. Cheng‐Mayer,et al. Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.
[119] R. Leduc,et al. Agonists for the Chemokine Receptor CXCR4 , 2011, ACS medicinal chemistry letters.
[120] Dominique Schols,et al. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. , 2002, The American journal of pathology.
[121] Y. Iwasaki,et al. Efficient inhibition of SDF‐1α‐mediated chemotaxis and HIV‐1 infection by novel CXCR4 antagonists , 2009, Cancer science.
[122] A. Peled,et al. Critical Involvement of the Chemotactic Axis CXCR4/Stromal Cell-Derived Factor-1α in the Inflammatory Component of Allergic Airway Disease , 2000, The Journal of Immunology.
[123] C. Broder,et al. Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry* , 2000, The Journal of Biological Chemistry.
[124] H. Goldschmidt,et al. First Results of a Phase-II Study with the New CXCR4 Antagonist POL6326 to Mobilize Hematopoietic Stem Cells (HSC) In Multiple Myeloma (MM) , 2010 .
[125] T. Nanki,et al. Cytokine, activation marker, and chemokine receptor expression by individual CD4+ memory T cells in rheumatoid arthritis synovium , 2000, Arthritis research.
[126] M. Konopleva,et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins , 2002, Leukemia.
[127] B. Pike,et al. Colony growth of human leukemic peripheral blood cells in vitro. , 1971, Blood.
[128] Naoki Yamamoto,et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[129] Stephen C Peiper,et al. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. , 2007, Journal of medicinal chemistry.
[130] N. Heveker,et al. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity , 1997, Journal of virology.
[131] E. Clercq,et al. Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.
[132] Anthony Atala,et al. Stem cells: cross-talk and developmental programs. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[133] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[134] E. Fernandez,et al. Comparison of the structure of vMIP-II with eotaxin-1, RANTES, and MCP-3 suggests a unique mechanism for CCR3 activation. , 2000, Biochemistry.
[135] Z. Huang,et al. Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. , 2000, Pharmacology & therapeutics.
[136] Richard P. Harvey,et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 , 2007, Proceedings of the National Academy of Sciences.
[137] John J Irwin,et al. Virtual screening against metalloenzymes for inhibitors and substrates. , 2005, Biochemistry.
[138] R. Bronson,et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[139] Michael Greenberg,et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1α is mediated by the chemokine receptor CXCR4 , 1998, Current Biology.
[140] B. Sykes,et al. Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.
[141] Hiroaki Mitsuya,et al. Diverse Transcriptional Response of CD4+ T Cells to Stromal Cell-Derived Factor (SDF)-1: Cell Survival Promotion and Priming Effects of SDF-1 on CD4+ T Cells1 , 2001, The Journal of Immunology.
[142] Z. Luo,et al. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. , 2000, Biochemistry.
[143] Elias Lolis,et al. Structure, function, and inhibition of chemokines. , 2002, Annual review of pharmacology and toxicology.
[144] S. Mummidi,et al. CC Chemokine Receptor 5-Mediated Signaling and HIV-1 Co-receptor Activity Share Common Structural Determinants , 1997, The Journal of Biological Chemistry.
[145] H. Broxmeyer,et al. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. , 1998, Blood.
[146] J. Lord,et al. Within the Rheumatoid Synovium Cells Contributes to Their Accumulation 1 on Synovial T b Receptor CXCR4 by TGF-Persistent Induction of the Chemokine , 2000 .
[147] D. Glass,et al. Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy , 1996 .
[148] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[149] F. de Wolf,et al. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV‐1 phenotype , 1992, AIDS.
[150] H. Tamamura,et al. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis , 2005, Expert opinion on therapeutic targets.
[151] F. Lezoualc’h,et al. Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers. , 2008, Current Drug Discovery Technologies.
[152] T. Narumi,et al. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. , 2010, Journal of the American Chemical Society.
[153] J. Demartino,et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[154] X Zhang,et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.
[155] Pallavi Sachdev,et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells , 2010, Proceedings of the National Academy of Sciences.
[156] Helen M. Blau,et al. Biological Progression from Adult Bone Marrow to Mononucleate Muscle Stem Cell to Multinucleate Muscle Fiber in Response to Injury , 2002, Cell.
[157] H. Yssel,et al. Cytokines and Cell Surface Molecules Independently Induce CXCR4 Expression on CD4+ CCR7+ Human Memory T Cells1 , 2000, The Journal of Immunology.
[158] E. Masliah,et al. Chemokine receptors and neurotrophic factors: Potential therapy against aids dementia? , 2008, Journal of neuroscience research.
[159] E. Estey,et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias , 2006, Molecular Cancer Therapeutics.
[160] B. Cullen,et al. HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.
[161] B. Yoo,et al. Plerixafor for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma , 2010, The Annals of pharmacotherapy.
[162] Samia J. Khoury,et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1α/CXC chemokine receptor 4 pathway , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[163] C. Martínez-A,et al. The chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[164] Michel Bouvier,et al. Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers* , 2005, Journal of Biological Chemistry.
[165] A. LiWang,et al. The solution structure of the anti‐HIV chemokine vMIP‐II , 1999, Protein science : a publication of the Protein Society.
[166] J. Karn,et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[167] Susan R. George,et al. G-Protein-coupled receptor oligomerization and its potential for drug discovery , 2002, Nature Reviews Drug Discovery.
[168] Shay Bar-Haim,et al. G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[169] Kouji Matsushima,et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.
[170] M. Matsuoka,et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. , 2001, Bioorganic & medicinal chemistry letters.
[171] E. Snyder,et al. Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. , 2003, Physiological genomics.
[172] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[173] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[174] E. De Clercq,et al. Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. , 2011, Bioorganic & medicinal chemistry letters.
[175] J. An,et al. Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.
[176] M. Matsuoka,et al. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. , 2010, Organic & biomolecular chemistry.
[177] M. Arai,et al. Importance of recruitment of bone marrow-derived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. , 2006, Cardiovascular research.
[178] P. O'Byrne,et al. The trials and tribulations of IL-5, eosinophils, and allergic asthma. , 2001, The Journal of allergy and clinical immunology.
[179] P. Lipsky,et al. Functional CD 40 Ligand Is Expressed by T Cells in Rheumatoid Arthritis , 2013 .
[180] Ido D. Weiss,et al. Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F‐Benzoyl‐TN14003 , 2007, Stem cells.
[181] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[182] Stephen C Peiper,et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. , 2003, Angewandte Chemie.
[183] D. Richman,et al. SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. , 2006, Chemistry & biology.
[184] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[185] J. Arbeit,et al. c-Jun is essential for organization of the epidermal leading edge. , 2003, Developmental cell.
[186] M. Feldmann,et al. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. , 1995, Arthritis and rheumatism.
[187] D. Wong,et al. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. , 2005, Experimental hematology.
[188] D. Link,et al. AMD 3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism , 2006 .
[189] David J. Daniels,et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[190] S. Nishikawa,et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.
[191] J. Hall,et al. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. , 2000, Biochemistry.
[192] S. Jenkinson,et al. Blockade of X4-Tropic HIV-1 Cellular Entry by GSK812397, a Potent Noncompetitive CXCR4 Receptor Antagonist , 2009, Antimicrobial Agents and Chemotherapy.
[193] J. Hoxie,et al. CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons , 1997, Current Biology.
[194] K. Chung,et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.
[195] Christie M. Orschell,et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.
[196] C. Boshoff,et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. , 1997, Science.
[197] G. Lambeau,et al. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. , 2001, Molecular pharmacology.
[198] B. Premack,et al. Chemokine receptors: Gateways to inflammation and infection , 1996, Nature Medicine.
[199] T. Kipps,et al. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. , 1999, Blood.
[200] Masahiko Kuroda,et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.
[201] A. Nagler,et al. Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. , 2002, Blood.
[202] James W. Hall,et al. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. , 1999, Biochemical and Biophysical Research Communications - BBRC.